CWM
MRTX

Catamount Wealth Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Catamount Wealth Management’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-100
Closed -$5K – 233
2018
Q3 		$5K Hold
100
– – ﹤0.01% 167
2018
Q2 		$6K Hold
100
– – ﹤0.01% 157
2018
Q1 		$3K Sell
100
-300
-75% -$8.33K ﹤0.01% 170
2017
Q4 		$7K Sell
400
-750
-65% -$11.6K ﹤0.01% 148
2017
Q3 		$13K Buy
+1,150
New +$6.65K 0.01% 126

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Catamount Wealth Management's MRTX Position: Q4 2018 in Review

Catamount Wealth Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2018, closing a stake of 100 shares — an estimated $5K sold.

Catamount Wealth Management first reported a position in MRTX in Q3 2017 and held it in 5 quarters. The position peaked at $13K in Q3 2017. 112 funds tracked by Wall St. Rank hold MRTX as of Q4 2018.

  • Catamount Wealth Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • Catamount Wealth Management sold 100 Mirati Therapeutics, Inc. Common Stock shares in Q4 2018, an estimated $5K.
  • Catamount Wealth Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2017 and held it in 5 quarters.
  • Catamount Wealth Management's Mirati Therapeutics, Inc. Common Stock position peaked at $13K in Q3 2017.
  • 112 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2018.

Based on Catamount Wealth Management's 13F filing for Q4 2018, filed 13 Feb 2019.